NCT03573115View on ClinicalTrials.gov

Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

July 18, 2018

Study Completion Date

August 1, 2020

Conditions
Acne VulgarisMicroparticles
Interventions
DRUG

Adapalene-Benzoyl Peroxide Gel 0.1-2.5%

Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)

Trial Locations (1)

2400

Bispebjerg Hospital, Department of Dermatology, Copenhagen

All Listed Sponsors
collaborator

Sebacia, Inc.

INDUSTRY

lead

Merete Haedersdal

OTHER

NCT03573115 - Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery | Biotech Hunter | Biotech Hunter